Citius Pharmaceuticals
CTXR
72 hedge funds and large institutions have $17.9M invested in Citius Pharmaceuticals in 2024 Q2 according to their latest regulatory filings, with 19 funds opening new positions, 16 increasing their positions, 18 reducing their positions, and 20 closing their positions.
0% less ownership
Funds ownership: 0.68% → 0.68% (-0%)
5% less first-time investments, than exits
New positions opened: 19 | Existing positions closed: 20
1% less funds holding
Funds holding: 73 → 72 (-1)
11% less repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 18
26% less capital invested
Capital invested by funds: $24.2M → $17.9M (-$6.35M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$7.28M |
| 2 |
Millennium Management
New York
|
+$1.47M |
| 3 |
Goldman Sachs
New York
|
+$788K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$451K |
| 5 |
YIH
Y-Intercept (HK)
Hong Kong
|
+$279K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$4.96M |
| 2 |
State Street
Boston,
Massachusetts
|
-$1.17M |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
-$931K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
-$486K |
| 5 |
N
Nuveen
Charlotte,
North Carolina
|
-$435K |
CTXR Hedge Fund Activity: Q2 2024 in Review
72 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Citius Pharmaceuticals (CTXR) for Q2 2024, worth a combined $17.9M — down 26% from $24.2M a quarter earlier.
Sellers outnumbered buyers: 20 funds closed out of CTXR and 19 opened new positions — a net loss of 1 holder — while 18 trimmed existing stakes and 16 added.
The largest buyer was Armistice Capital, opening a new position worth an estimated $7.28M. The largest seller was BlackRock, cutting an estimated $4.96M.
- 72 institutional investors held Citius Pharmaceuticals (CTXR) as of Q2 2024, down from 73 in Q1 2024.
- Funds reported $17.9M of Citius Pharmaceuticals stock for Q2 2024, down 26% quarter-over-quarter.
- 19 funds opened new Citius Pharmaceuticals positions in Q2 2024 and 20 closed out, a net change of -1 holder.
- The largest Citius Pharmaceuticals buyer in Q2 2024 was Armistice Capital, an estimated $7.28M added.
- The largest Citius Pharmaceuticals seller in Q2 2024 was BlackRock, an estimated $4.96M sold.
Based on aggregated 13F filings for Q2 2024.